Scientists Fish For Answers About Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a leading cause of cancer-related deaths worldwide. Although there are several treatment options available, they are largely unsuccessful because the disease is so poorly understood. Clinical studies of patients with HCC, combined with studies using mice and other animal models, have provided some clues, but many questions about how to diagnose and treat this deadly form of cancer remain. Zhiyuan Gong and Serguei Parinov from the National University of Singapore decided to pursue these questions using zebrafish as a model system.
Advaxis Granted Pre-IND Meeting With The FDA For Advaxis-PSA Prostate Immunotherapy
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer. The product is being manufactured by Advaxis' contractor, Vibalogics, in Germany. The Company plans to file the IND application later this year to initiate a Phase I/II safety study in humans.
Visiongate To Present At IASLC Meeting Showing How Adjunctive Use Of Its 3d Cell Imaging Platform Can Increase Utility Of CT Screening For Lung Cancer
VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today announced that it will present data showing how adjunctive use of its LuCED™ test can improve the utility of low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals. LuCED uses VisionGate's revolutionary automated 3D cell imaging platform, the Cell-CT™ , which generates high-resolution 3D biosignatures from intact cells using a sputum sample.